CXCL8 and liver cancer: In this study, we demonstrated that in JHH6 hepatic cancer cells, E3330 treatment inhibits TNF-α-induced IL8 production through impairment of APE1 subcellular distribution, thus confirming a novel aspect of E3330 effect on APE1 modulation.